Navigation Links
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. -- AMAG

NEW YORK, Sept. 25, 2013 /PRNewswire/ -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP is investigating claims on behalf of investors of AMAG Pharmaceuticals, Inc. ("AMAG" or the "Company")(NASDAQ: AMAG).  Such investors are advised to contact Robert S. Willoughby at or 888-476-6529, ext. 237.

The investigation concerns whether AMAG and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.  On December 21, 2012, AMAG submitted to the U.S. Food and Drug Administration (the "FDA") a supplemental New Drug Application (the "sNDA") under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Feraheme (ferumoxytol) Injection, 510 mg. The sNDA sought approval for a broader indication for Feraheme for the treatment of iron deficiency anemia in adult patients who have failed or could not use oral iron. On September 23, 2013, the Company received a notification from the FDA stating that, as part of its ongoing review of the Company's sNDA, the FDA has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments by September 23, 2013, a target date previously communicated by the FDA in a letter dated March 5, 2013.  On September 25, 2013 the Company announced in an Securities and Exchange Commission Form 8-K filing, information regarding the FDA notification received on September 23, 2013.

On this news, shares of AMAG fell $3.09 per share to more than 11.81% on intraday trading to a price of  $23.07 on September 25, 2013.

The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See

Robert S. Willoughby
Pomerantz Grossman Hufford Dahlstrom & Gross LLP

SOURCE Pomerantz Grossman Hufford Dahlstrom & Gross LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. China Nepstar Chain Drugstore Schedules Annual General Meeting of Shareholders for October 25, 2013
2. SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Astex Pharmaceuticals, Inc.
3. Buyout Alert -- Astex Pharmaceuticals -- Law Firm Seeks Higher Price For Shareholders
4. Hi Tech Shareholder Alert - Buyout Of Hi Tech - Law Firm Seeks Higher Price For Shareholders
5. Shareholder Alert: Pomerantz Law Firm has filed a Class Action Against Biolase, Inc. and Certain Officers - BIOL
6. Acquisition of Onyx Pharmaceuticals, Inc. by Amgen Inc. May Not Be in the Best Interests of Onyx Pharmaceuticals, Inc. Shareholders
7. Concord Medical Announces Acquisition of Its Shares by CEO and COO from Other Shareholders
8. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
9. FDA Approvals, Dividends, New Technologies, and Solid Margins Increase Shareholder Value - Research Report on Abbott, Baxter, CareFusion, Haemonetics, and CR Bard
10. Teamsters Protest McKessons Worker Abuse And Executive Pay At Shareholder Meeting
11. Alliquas CEO Issues Midyear Corporate Update for Shareholders
Post Your Comments:
(Date:11/25/2015)... 25, 2015 - Will Also ... (CME) --> - Will ... Education (CME) --> - Will ... Continuing Medical Education (CME) Elsevier , ... services, will feature latest diagnostic imaging textbooks and decision support tools, ...
(Date:11/24/2015)... 25, 2015 The hope of ... failure of IVF cycles. After failure of over 15 ... had lost all hopes that she would be able to conceive ever. But finally optimism ... conceived after failure of over 15 IVF cycles. ... they decided to take one last attempt with Gaudium IVF Center in ...
(Date:11/24/2015)... 24, 2015  Array BioPharma Inc. (Nasdaq: ... Officer, Ron Squarer , will present at ... York.  The public is welcome to participate in ... BioPharma website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  , Ron ... 2015Time:1:30 p.m. Eastern Time Webcast: , ...
Breaking Medicine Technology:
(Date:11/25/2015)... IL (PRWEB) , ... November 25, 2015 , ... ... to six decades of music, friendships, and learning in its 65th Anniversary Brillianteen ... held Dec. 5-6. , For 65 years, Brillianteen has been a ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Today, Mothers ... our nation’s roadways has dropped below 10,000 for the first time since 2011. In ... 2013. , According to data released by the National Highway Traffic Safety Administration (NHTSA), ...
(Date:11/25/2015)... ... November 25, 2015 , ... "When ... that regular bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. "In ... She developed the patent-pending RECOVERY BRA for added comfort and support. The bra ...
(Date:11/25/2015)... ... , ... Many people know of the common symptoms of low thyroid hormone ... But many people who find their cholesterol levels and weight are creeping up are ... if they don’t have any of the other symptoms. , Thyroid hormone plays a ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to be thankful ... Create Real Impact awards. California Casualty is proud to support the contest ... distracted and reckless driving, the number one killer of young drivers. , Almost ...
Breaking Medicine News(10 mins):